Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Cancer Moonshot

National Cancer Institute: Cancer Moonshot Moves Forward, Bringing Funding Opportunities for Researchers

Bethesda, MD, March 15, 2017Douglas R. Lowy, M.D., Acting Director, National Cancer Institute last month wrote:

The 21st Century Cures Act, which was signed into law in December 2016, authorizes $1.8 billion over 7 years to fund the Beau Biden Cancer Moonshot℠, $300 million of which is available in Fiscal Year 2017.

These funds enable NCI to begin, this fiscal year, implementing cancer research initiatives that align with the goals outlined in last fall’s report from the Cancer Moonshot Blue Ribbon Panel (BRP) and to rapidly build on progress that NCI and its many research partners have achieved over the years. Continue reading

Opinion: Vice President Joe Biden Won’t Keep Quiet Against Cancer

Biden and ObamaWashington, DC, January 14, 2017Robert Goldberg, Vice President, Center for Medicine in the Public Interest, writes in The Hill:

Vice President Joe Biden won’t be playing a lot of golf after he leaves office. Instead, he will continue to take his whacks against cancer through a new non-profit that will carry on the mission of the Cancer Moonshot program he chaired.

A Washington Post article reports that the new organization will continue to advance the Moonshot goals, “including the need to knock down “silos” in cancer research and share research data and medical records more widely, boosting participation in clinical trials, and finding new ways to improve treatment provided by community oncologists. Continue reading

National Cancer Institute and Drug Companies Aim to Speed Up Clinical Trials

nih-national-cancer-instituteBethesda, MD, January 13, 2017 — The National Cancer Institute (NCI) on January 11 launched a new drug formulary (the “NCI Formulary”) that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.

The NCI Formulary could ultimately translate into speeding the availability of more-effective treatment options to patients with cancer.

The NCI Formulary is a public-private partnership between NCI, part of the National Institutes of Health, and pharmaceutical and biotechnology companies. Continue reading

VP Biden Outlines Steps to Pursue Post-Obama ‘Cancer Moonshot’

Vice President Joe Biden

Vice President Joe Biden

Washington, DC, January 11, 2017 — Vice President Joe Biden is outlining how he intends to pursue his “cancer moonshot” agenda after the end of the Obama administration, the Associated Press reports.

Biden says in a San Francisco speech that he will be starting an organization that may be called the Biden Cancer Initiative to make progress in changing the way the nation conducts cancer research and development and providing care to those with the disease. Continue reading

Congress Passes 21st Century Cures Act; President Obama Praises Bill to Accelerate Medical Innovation

21st-century-cures-blueWashington, DC, December 8, 2016 — Mike DeBonis reports in The Washington Post that Congress passed sweeping legislation yesterday that boosts funding for medical research, eases the development and approval of experimental treatments and reforms federal policy on mental health care.

The 94 to 5 Senate vote Wednesday followed a 392 to 26 House vote last week.

The bill, known as the 21st Century Cures Act, now heads to the desk of President Obama, who praised the bill Wednesday and said he would sign it. Continue reading

U.S. House Approves 21st Century Cures Bill, A Sweeping Health, Medical Innovation Measure

21st-century-cures-blueWashington, DC, December 1, 2016 — Jennifer Steinhauer and Sabrina Tavernise report in The New York Times that the U.S. House or Representatives yesterday overwhelmingly passed a far-reaching measure — the 21st Century Cures Act — to increase funding for research into cancer and other diseases, address weaknesses in the nation’s mental health systems and help combat the prescription drug addictions that have bedeviled nearly every state.

In a statement, House Energy and Commerce Committee Chairman Fred Upton (R-MI) and Rep. Diana DeGette (D-CO), co-authors of the bill, said, “21st Century Cures is the innovation game-changer that patients, their loved ones, and the nation’s researchers and scientists so desperately need.”

“The White House has expressed its enthusiastic endorsement of this critical legislation,” Upton and DeGette said.  “So it’s now on to the Senate, where we are just one final vote away from delivering #CuresNow.” Continue reading

21st Century Cures Bill Released; House to Vote Wednesday on $6.3 Billion Medical Innovation Package

Capitol Building flagWashington, DC, November 28, 2016 — U.S. House of Representatives and Senate health committee leaders have released the final “21st Century Cures” bill.

In addition, the leaders announced that the House will vote Wednesday on a $6.3 Billion landmark medical innovation package that will accelerate the discovery, development, and delivery of new cures and treatments and provide new funding for the National Institutes of Health (NIH) and Food and Drug Administration (FDA).

The leaders said the House also will vote Wednesday to include in the Cures bill legislation that updates major mental health programs for the first time in a decade.   Continue reading

VP Biden’s Cancer ‘Moonshot’ Project Hangs in Balance as Trump Readies for Presidency

Vice President Joe Biden

Vice President Joe Biden

 Washington, DC, November 26, 2016 — Dylan Scott reports in STAT that Vice President Joe Biden’s cancer “moonshot” is in serious jeopardy following Donald Trump’s election, but there may be hope for it yet.

The president-elect hasn’t said anything about the initiative, launched by the Obama administration earlier this year, and his aides didn’t reply to multiple requests for comment.

But the lame-duck Congress is making a last-ditch effort to pass a medical innovation bill that would provide hundreds of millions of dollars in funding for the effort. Continue reading

Opinion: For Medical Miracles, Empower Life Sciences Companies — Don’t Vilify Them

Medical Innovation 6Washington, DC, October 28, 2016Former United States Senator Tom Coburn, M.D., and Paul Howard, Ph.D., director of health policy, Manhattan Institute, and co-author of the new book, “Unlocking Precision Medicine,” write in The Hill:

“We can do virtually anything,” Vice President Joe Biden told the Cleveland crowd. “Your children are going to see more progress in the next 15 years than we’ve seen in the last 75 years.”

With these words, Biden opened the Cleveland Clinic’s medical innovation summit on Monday. The progress he spoke of is in the fight against cancer, where the next generation of American cures is set to radically shift the medical landscape. Continue reading

STAT: VP Biden Unveils ‘Cancer Moonshot’ Report; Here Are 3 Big Projects the White House Is Pursuing

STATWashington, DC, October 18, 2016 — Dylan Scott reports on STAT that the White House’s cancer moonshot, the future of which Vice President Joe Biden outlined in a new report on October 17, has a lot of moving parts.

The report details nearly 20 projects that are already underway or soon will be in the moonshot’s first year and another two dozen planned for its second year and beyond.

Major themes include harnessing big data, sharing research among scientists, and expanding preventive measures like the HPV vaccine and colorectal cancer screening.  Some of these efforts will be run by the government; others are being led by the private sector.

Here are three big projects that caught our eye. Continue reading